X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs SUN PHARMA - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER SUN PHARMA PFIZER/
SUN PHARMA
 
P/E (TTM) x 32.9 46.5 70.8% View Chart
P/BV x 4.9 3.8 130.5% View Chart
Dividend Yield % 0.8 0.6 126.1%  

Financials

 PFIZER   SUN PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-17
SUN PHARMA
Mar-17
PFIZER/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs2,055842 244.0%   
Low Rs1,651572 288.5%   
Sales per share (Unadj.) Rs429.8131.6 326.5%  
Earnings per share (Unadj.) Rs73.632.7 225.1%  
Cash flow per share (Unadj.) Rs87.438.0 230.1%  
Dividends per share (Unadj.) Rs20.003.50 571.4%  
Dividend yield (eoy) %1.10.5 218.1%  
Book value per share (Unadj.) Rs528.7152.7 346.2%  
Shares outstanding (eoy) m45.752,399.26 1.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.35.4 80.2%   
Avg P/E ratio x25.221.6 116.4%  
P/CF ratio (eoy) x21.218.6 113.9%  
Price / Book Value ratio x3.54.6 75.7%  
Dividend payout %27.210.7 253.9%   
Avg Mkt Cap Rs m84,7771,696,877 5.0%   
No. of employees `0002.817.5 16.2%   
Total wages/salary Rs m3,03949,023 6.2%   
Avg. sales/employee Rs Th6,925.918,028.3 38.4%   
Avg. wages/employee Rs Th1,070.42,798.8 38.2%   
Avg. net profit/employee Rs Th1,186.34,479.5 26.5%   
INCOME DATA
Net Sales Rs m19,663315,784 6.2%  
Other income Rs m1,0126,232 16.2%   
Total revenues Rs m20,674322,016 6.4%   
Gross profit Rs m3,491100,893 3.5%  
Depreciation Rs m62912,648 5.0%   
Interest Rs m103,998 0.2%   
Profit before tax Rs m3,86490,479 4.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m1,3040-   
Tax Rs m1,80112,116 14.9%   
Profit after tax Rs m3,36878,462 4.3%  
Gross profit margin %17.831.9 55.6%  
Effective tax rate %46.613.4 348.0%   
Net profit margin %17.124.8 68.9%  
BALANCE SHEET DATA
Current assets Rs m20,789329,537 6.3%   
Current liabilities Rs m7,870178,870 4.4%   
Net working cap to sales %65.747.7 137.7%  
Current ratio x2.61.8 143.4%  
Inventory Days Days6079 75.7%  
Debtors Days Days2283 26.9%  
Net fixed assets Rs m9,175204,766 4.5%   
Share capital Rs m4582,399 19.1%   
"Free" reserves Rs m23,731363,997 6.5%   
Net worth Rs m24,189366,397 6.6%   
Long term debt Rs m2514,361 0.2%   
Total assets Rs m32,706614,102 5.3%  
Interest coverage x403.523.6 1,707.5%   
Debt to equity ratio x00 2.6%  
Sales to assets ratio x0.60.5 116.9%   
Return on assets %10.313.4 76.9%  
Return on equity %13.921.4 65.0%  
Return on capital %21.424.8 86.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6344,118 0.1%   
Fx outflow Rs m4,06724,484 16.6%   
Net fx Rs m-4,00419,634 -20.4%   
CASH FLOW
From Operations Rs m3,28870,822 4.6%  
From Investments Rs m-2,496-42,216 5.9%  
From Financial Activity Rs m-826-22,854 3.6%  
Net Cashflow Rs m-356,107 -0.6%  

Share Holding

Indian Promoters % 0.0 63.7 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 5.1 146.2%  
FIIs % 4.9 23.0 21.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 8.3 285.5%  
Shareholders   85,207 133,026 64.1%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  BIOCON LTD  FULFORD INDIA  

Compare PFIZER With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Cuts Losses; TCS Up 3%(Closing)

After opening the day in red, share markets in India witnessed volatile trading activity throughout the day but clawed back some gains in the final hours of the trading window.

Related Views on News

SUN PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 12.0%

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, SUN PHARMA has posted a net profit of Rs 16 bn (up 12.0% YoY). Sales on the other hand came in at Rs 70 bn (down 2.2% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Jun 15, 2018 (Close)

TRACK PFIZER

COMPARE PFIZER WITH

MARKET STATS